达格列净在心力衰竭患者中按衰弱分层的疗效与安全性:DELIVER 试验预设分析
DELIVER 试验预设分析纳入 6263 例射血分数轻度降低或保留的心衰患者,用 Rockwood 累积缺陷法计算衰弱指数并分为 3 类。结果显示衰弱越重主要终点事件率越高,达格列净在各衰弱类别中获益一致,且衰弱最重者生活质量改善更明显,不良反应与停药率在达格列净组与安慰剂组间无差异。
要点
- 衰弱越重主要终点事件率越高,但达格列净在各衰弱类别中疗效一致。
- 衰弱最重者使用达格列净后 4 个月生活质量改善幅度更大。
- 各衰弱类别中达格列净的不良反应与停药率均未高于安慰剂。
核心结论
- DELIVER 试验中衰弱常见且与更差结局相关,达格列净在所研究的衰弱范围内获益一致。
- 达格列净对健康相关生活质量的改善出现较早,且在衰弱程度更高的患者中改善更大。
研究设计与样本
- DELIVER 试验预设分析,随机分组 6263 例心衰且射血分数轻度降低或保留的患者,6258 例可计算衰弱指数。
- 衰弱采用 Rockwood 累积缺陷法测量,按衰弱指数分为 3 类:1 类≤0.210 为不衰弱,2 类 0.211–0.310 为较衰弱,3 类≥0.311 为最衰弱。
- 主要终点为首次心衰恶化事件或心血管死亡的时间。
主要发现
- 1 类 2354 例(37.6%)、2 类 2413 例(38.6%)、3 类 1491 例(23.8%)。
- 主要终点率(每 100 人年):1 类 6.3(95%CI 5.7–7.1),2 类 8.3(7.5–9.1),3 类 13.4(12.1–14.7),P<0.001。
- 达格列净对主要终点的风险比:1 类 0.85(95%CI 0.68–1.06),2 类 0.89(0.74–1.08),3 类 0.74(0.61–0.91),Pinteraction=0.40。
- 4 个月 KCCQ 总体汇总评分安慰剂校正改善:1 类 0.3(95%CI -0.9 至 1.4),2 类 1.5(0.3–2.7),3 类 3.4(1.7–5.1),Pinteraction=0.021。
- 不良反应与治疗停药在衰弱更重者中更常见,但无论衰弱类别,达格列净组均未较安慰剂组更常见。
临床怎么用
- 对射血分数轻度降低或保留的心衰患者,不应因衰弱而排除达格列净治疗。
- 衰弱程度更高的患者使用达格列净可能获得更大的早期生活质量改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure). METHODS: Frailty was measured using the Rockwood cumulative deficit approach. The primary end point was time to a first worsening heart failure event or cardiovascular death. RESULTS: Of the 6263 patients randomized, a frailty index (FI) was calculable in 6258. In total, 2354 (37.6%) patients had class 1 frailty (FI ≤0.210; ie, not frail), 2413 (38.6%) had class 2 frailty (FI 0.211-0.310; ie, more frail), and 1491 (23.8%) had class 3 frailty (FI ≥0.311; ie, most frail). Greater frailty was associated with a higher rate of the primary end point (per 100 person-years): FI class 1, 6.3 (95% CI 5.7-7.1); class 2, 8.3 (7.5-9.1); and class 3, 13.4 (12.1-14.7; P<0.001). The effect of dapagliflozin (as a hazard ratio) on the primary end point from FI class 1 to 3 was 0.85 (95% CI, 0.68-1.06), 0.89 (0.74-1.08), and 0.74 (0.61-0.91), respectively (Pinteraction=0.40). Although patients with a greater degree of frailty had worse Kansas City Cardiomyopathy Questionnaire scores at baseline, their improvement with dapagliflozin was greater than it was in patients with less frailty: placebo-corrected improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary Score at 4 months in FI class 1 was 0.3 (95% CI, -0.9 to 1.4); in class 2, 1.5 (0.3-2.7); and in class 3, 3.4 (1.7-5.1; Pinteraction=0.021). Adverse reactions and treatment discontinuation, although more frequent in patients with a greater degree of frailty, were not more common with dapagliflozin than with placebo irrespective of frailty class. CONCLUSIONS: In DELIVER, frailty was common and associated with worse outcomes. The benefit of dapagliflozin was consistent across the range of frailty studied. The improvement in health-related quality of life with dapagliflozin occurred early and was greater in patients with a higher level of frailty. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03619213.
引用
- Butt, Jhund, Belohlávek, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022. PMID: 36029465. doi:10.1161/CIRCULATIONAHA.122.061754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。